Amgen beats with $6.45 adjusted EPS, raises 2026 revenue guide to $38.9-$39.7 billion
Reuters · · AI-summarised by FinFlash
Amgen's third-quarter sales rose 8% to The beat and raise support large-cap biotech sentiment, with newer drugs outrunning Prolia's decline. Watch tomorrow's reaction in AMGN and peers for confirmation. Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.So What?
Understand the context